Healthcare -
Medical - Healthcare Information Services - NASDAQ - CH
$ 2.99
-1.64 %
$ 200 M
Market Cap
-2.99
P/E
1. INTRINSIC VALUE
Balance Sheet
SOPHiA GENETICS S.A.
| Current Assets | 99.4 M |
| Cash & Short-Term Investments | 80.2 M |
| Receivables | 8.69 M |
| Other Current Assets | 10.5 M |
| Non-Current Assets | 55.9 M |
| Long-Term Investments | 0 |
| PP&E | 19.4 M |
| Other Non-Current Assets | 36.5 M |
| Current Liabilities | 26.8 M |
| Accounts Payable | 1.93 M |
| Short-Term Debt | 2.19 M |
| Other Current Liabilities | 22.7 M |
| Non-Current Liabilities | 32 M |
| Long-Term Debt | 27.8 M |
| Other Non-Current Liabilities | 4.18 M |
EFFICIENCY
Earnings Waterfall
SOPHiA GENETICS S.A.
| Revenue | 65.2 M |
| Cost Of Revenue | 21.2 M |
| Gross Profit | 43.9 M |
| Operating Expenses | 111 M |
| Operating Income | -66.6 M |
| Other Expenses | -5.3 M |
| Net Income | -61.3 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
SOPHiA GENETICS S.A.
| Net Income | -61.3 M |
| Depreciation & Amortization | 8.6 M |
| Capital Expenditures | -8.18 M |
| Stock-Based Compensation | 16.5 M |
| Change in Working Capital | -2.58 M |
| Others | -4.49 M |
| Free Cash Flow | -51 M |
Wall Street Analysts Price Targets
SOPHiA GENETICS S.A.
Wall Street analysts predict an average 1-year price target for SOPH of $5.33 , with forecasts ranging from
a
low of
$5 to a high of $6 .
SOPH Lowest Price Target
Wall Street Target
5 USD
67.22%
SOPH Average Price Target
Wall Street Target
5.33 USD
78.37%
SOPH Highest Price Target
Wall Street Target
6 USD
100.67%
4. DIVIDEND
ANALYSIS
SOPH does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
SOPHiA GENETICS S.A.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
SOPHiA GENETICS SA (NASDAQ:SOPH) Shares Sold by Squarepoint Ops LLC
Squarepoint Ops LLC lowered its position in SOPHiA GENETICS SA (NASDAQ:SOPH – Free Report) by 30.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,753 shares of the company’s stock after selling 5,886 shares during the quarter. Squarepoint Ops LLC’s holdings in SOPHiA GENETICS were worth $43,000 at the end of the most recent quarter. Other institutional investors have also recently added to or reduced their stakes in the company. Federated Hermes Inc. raised its stake in shares of SOPHiA GENETICS by 40.5% in the 4th quarter. Federated Hermes Inc. now owns 100,000 shares of the company’s stock valued at $312,000 after purchasing an additional 28,819 shares in the last quarter. Dimensional Fund Advisors LP grew its position in SOPHiA GENETICS by 23.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 21,619 shares of the company’s stock worth $68,000 after purchasing an additional 4,115 shares during the last quarter. Finally, Millennium Management LLC boosted its holdings in shares of SOPHiA GENETICS by 6.5% in the fourth quarter. Millennium Management LLC now owns 698,634 shares of the company’s stock valued at $2,180,000 after acquiring an additional 42,689 shares in the last quarter. Institutional investors and hedge funds own 31.59% of the company’s stock. SOPHiA GENETICS Stock Performance NASDAQ SOPH opened at $2.99 on Wednesday. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.80 and a quick ratio of 3.59. The firm has a market capitalization of $199.39 million, a price-to-earnings ratio of -2.74 and a beta of 1.00. The company’s fifty day moving average is $2.95 and its two-hundred day moving average is $3.26. SOPHiA GENETICS SA has a 52-week low of $2.58 and a 52-week high of $5.05. SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative return on equity of 55.06% and a negative net margin of 110.71%. The business had revenue of $17.78 million for the quarter, compared to the consensus estimate of $16.76 million. Equities research analysts forecast that SOPHiA GENETICS SA will post -0.96 EPS for the current year. Wall Street Analyst Weigh In Separately, BTIG Research set a $5.00 target price on shares of SOPHiA GENETICS in a report on Thursday, March 6th. Read Our Latest Research Report on SOPHiA GENETICS About SOPHiA GENETICS (Free Report) SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.
https://www.defenseworld.net
- 4 weeks ago
SOPHiA GENETICS SA (SOPH) Q1 2025 Earnings Call Transcript
SOPHiA GENETICS SA. (NASDAQ:SOPH ) Q1 2025 Earnings Conference Call May 6, 2025 8:00 AM ET Company Participants Kellen Sanger - Head, Strategy and Investor Relations Jurgi Camblong - Co-Founder and Chief Executive Officer Ross Muken - President George Cardoza - Chief Financial Officer Conference Call Participants William Bonello - Craig-Hallum Conor McNamara - RBC Capital Markets Subbu Nambi - Guggenheim Operator Good morning, ladies and gentlemen, and welcome to the SOPHiA GENETICS Q1 2025 Earnings Call.
seekingalpha.com
- 1 month ago
SOPHiA GENETICS SA (SOPH) Reports Q1 Loss, Tops Revenue Estimates
SOPHiA GENETICS SA (SOPH) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.21 per share a year ago.
zacks.com
- 2 months ago
SOPHiA GENETICS Reports First Quarter 2025 Results
BOSTON and ROLLE, Switzerland , May 6, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Revenue was $17.8 million, up 13% year-over-year or 15% on a constant currency basis Gross margin was 68.7% on a reported basis and 75.7% on an adjusted basis, up from 65.9% and 70.5% in the prior year period, respectively IFRS net loss increased 27% year-over-year to $17.4 million (including a net foreign exchange P&L impact of $5.2 million), and adjusted EBITDA loss improved 24% year-over-year to $9.8 million The company reiterates full-year guidance of revenue between $72 million and $76 million and adjusted EBITDA loss between $35 million and $39 million "We started the year strong with year-over-year revenue growth of 13%, or 15% on a constant currency basis, as the large amount of new business signed in 2024 begins to ramp," said Jurgi Camblong, PhD.
prnewswire.com
- 2 months ago
SOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACR
BOSTON and ROLLE, Switzerland , April 28, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and global leader in data-driven medicine, today announced the expansion of its ongoing collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) to accelerate the deployment of MSK-ACCESS® powered with SOPHiA DDM™ globally. Building on the initial collaboration announced in October 2024 , this new phase will extend the test's reach to a total of 30 clinical institutions worldwide in 2025.
prnewswire.com
- 2 months ago
SOPHiA GENETICS to Announce Financial Results for First Quarter 2025 on May 6, 2025
BOSTON and ROLLE, Switzerland , April 22, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the first quarter 2025 before U.S. markets open on Tuesday, May 6, 2025. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m.
prnewswire.com
- 2 months ago
Precision for Medicine Partners with SOPHiA GENETICS to Expand Biopharma Services with the SOPHiA DDM™ Platform and its Liquid Biopsy Capabilities
The partnership integrates advanced AI-driven analytics and clinical trial solutions, empowering biopharma companies to accelerate drug development and deliver targeted therapies faster. BETHESDA, Md.
prnewswire.com
- 3 months ago
SOPHiA GENETICS (SOPH) Upgraded to Buy: What Does It Mean for the Stock?
SOPHiA GENETICS (SOPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com
- 3 months ago
SOPHiA GENETICS Announces Two Million Patient Cases Analyzed, Marking a New Milestone for Data-Driven Medicine at NVIDIA GTC
BOSTON, MA and ROLLE, Switzerland , March 18, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, has reached a historic milestone: more than two million patients genomic profiles analyzed on the AI-powered analytics Platform SOPHiA DDM™. This achievement solidifies SOPHiA GENETICS as the gold-standard provider of actionable insights for patient care, applying AI capabilities shaped by an unmatched dataset of diverse, real-world patient data.
prnewswire.com
- 3 months ago
SOPHiA GENETICS SA (SOPH) Q4 2024 Earnings Call Transcript
SOPHiA GENETICS SA (NASDAQ:SOPH ) Q4 2024 Earnings Call March 4, 2025 8:00 AM ET Company Participants Kellen Sanger - Head, Strategy and Investor Relations Jurgi Camblong - Co-Founder and Chief Executive Officer Ross Muken - President George Cardoza - Chief Financial Officer Conference Call Participants Subbu Nambi - Guggenheim Mark Massaro - BTIG Tejas Savant - Morgan Stanley Bill Bonello - Craig-Hallum Operator Good morning. My name is Liway and I'll be your conference operator today.
seekingalpha.com
- 4 months ago
SOPHiA GENETICS SA (SOPH) Reports Q4 Loss, Tops Revenue Estimates
SOPHiA GENETICS SA (SOPH) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.37 per share a year ago.
zacks.com
- 4 months ago
SOPHiA GENETICS Reports Fourth Quarter and Full Year 2024 Results
BOSTON and ROLLE, Switzerland , March 4, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for its fourth quarter and fiscal year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights Revenue was $17.7 million, up 4% year-over-year or 6% on a constant currency basis excluding COVID-19-related revenue Gross margin was 68.2% on a reported basis and 74.2% on an adjusted basis, compared to 69.8% and 73.4% in the prior year period, respectively Operating loss was $17.4 million on a reported basis and $10.2 million on an adjusted basis, representing year-over-year improvements of 8% and 23%, respectively Full Year 2024 Financial Highlights Revenue was $65.2 million, up 4% year-over-year or 5% on a constant currency basis excluding COVID-19-related revenue Gross margin was 67.4% on a reported basis and 72.8% on an adjusted basis, compared to 68.8% and 72.2% in the prior year period, respectively Operating loss was $66.6 million on a reported basis and $44.8 million on an adjusted basis, representing year-over-year improvements of 11% and 20%, respectively "We continued driving widespread adoption of SOPHiA DDM™ in 2024, achieving a record number of analyses, major new customers wins, and healthy volume growth during the year, despite BioPharma headwinds which impacted overall performance and resulted in softer revenue growth than we would have liked," said Jurgi Camblong, PhD.
prnewswire.com
- 4 months ago
8. Profile
Summary
SOPHiA GENETICS S.A. SOPH
COUNTRY
CH
INDUSTRY
Medical - Healthcare Information Services
MARKET CAP
$ 200 M
Dividend Yield
0.00%
Description
SOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, products, and services are used by hospital, laboratory, and biopharma worldwide. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Saint-Sulpice, Switzerland.
Contact
Rue du Centre 172, Rolle, 1025
https://www.sophiagenetics.com
IPO
Date
July 23, 2021
Employees
423
Officers
Mr. Ross Jordan Muken B.Sc.
President
Dr. Philippe Menu M.B.A., M.D., Ph.D.
Executive Vice President, Chief Medical Officer & Chief Product Officer
Mr. Kevin Puylaert
Vice President & MD of EMEA
Dr. Jurgi Camblong M.B.A., Ph.D.
Co-Founder, Chief Executive Officer & Director
Dr. Zhenyu Xu Ph.D.
Executive Vice President & Chief Scientific Officer
Kellen Sanger
Head of Strategy and Investor Relations
Mr. Daan van Well L.L.M., M.B.A.
Executive Vice President, Chief Legal & Regulatory Officer
Mr. George A. Cardoza M.B.A.
Executive Vice President & Chief Financial Officer
Ms. Manuela Da Silva Valente B.A.
Executive Vice President & Chief People Officer
Mr. Abhimanyu Verma
Senior Vice President & Chief Technology Officer